Restoration of inflammatory responsiveness by metformin in endothelial cells derived from Marfan syndrome patient-specific induced pluripotent stem cells
BACKGROUND Marfan syndrome (MFS) is a hereditary connective tissue disorder that considerably increases the risk of thoracic aortic aneurysm and dissection.Endothelial cell (EC) dysfunction is now widely regarded as a key contributor to the vascular pathology associated with MFS.AIM To characterize endothelial dysfunction in patient-specific induced pluripotent stem cellderived ECs (MFS-iECs) from patients with MFS and to determine whether metformin and resveratrol can ameliorate these abnormalities.METHODS MFS-induced pluripotent stem cells were reprogrammed from patient-derived cells and differentiated into ECs.EC proliferation, migration, angiogenesis, nitric oxide bioavailability, cellular senescence, and mitochondrial function were evaluated in MFS-iECs and wild-type iECs.Transcriptomic analysis was performed to characterize inflammatory signaling and responses to TNF-α stimulation.MFS-iECs were subsequently treated with metformin or resveratrol to assess their effects on endothelial inflammatory phenotypes.RESULTS Compared with wild-type-iECs, MFS-iECs exhibited impaired proliferation, migration, angiogenesis, and nitric oxide bioavailability, as well as accelerated cellular senescence and mitochondrial dysfunction.Transcriptomic analysis revealed hyperactivated inflammatory signaling, blunted responsiveness to TNF-α stimulation, and enhanced NF-κB pathway activity.Metformin partially restored inflammatory responsiveness to TNF-α in MFS-iECs without significantly altering basal inflammation or cellular senescence, whereas resveratrol dose-dependently suppressed basal proinflammatory cytokine expression.CONCLUSION These findings reveal profound endothelial dysfunction and inflammatory dysregulation in human MFS-iECs.Metformin and resveratrol modulate endothelial inflammation through distinct mechanisms, providing a novel translational basis for developing ECtargeted therapies in patients with MFS.
Authors
- Yongyu Wang (ORCID: https://orcid.org/0000-0002-6088-8887)
- Congkuo Du (ORCID: https://orcid.org/0000-0001-9865-3883)
- Lai Jin-biao
- Yongsheng Gong (ORCID: https://orcid.org/0000-0001-8383-2934)
- Peifeng Jin (ORCID: https://orcid.org/0000-0002-4933-9406)
- Min-Jie Hu
- Xue-Jiao Chen
- Run-Ze Dong
- Mi-Qi Zhou
- Xiao-Fang Fan
- Xiu-Fang Chen
- Lu Ding
- Xiao-Li Ren
- Yu-Hao Chen
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Wenzhou Municipal Sci-Tech Bureau (CN)
Publication Details
- Journal
- World Journal of Stem Cells
- Published
- 2026-11-13
- DOI
- https://doi.org/10.4252/wjsc.124057
- Primary Topic
- Connective tissue disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00